Table 4. Univariate and multivariate Cox regression analyses in the validation cohort.
| Variable | Univariate analysis | Multivariate analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RFS | OS | RFS | OS | ||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||
| Age, y (≤50 vs. >50) | 1.147 (0.697–1.890) | 0.589 | 1.492 (0.894–2.490) | 0.126 | NA | NA | NA | NA | |||
| Gender (male vs. female) | 1.136 (0.579–2.229) | 0.712 | 0.913 (0.477–1.758) | 0.783 | NA | NA | NA | NA | |||
| HBV | 1.328 (0.681–2.591) | 0.406 | 0.982 (0.515–1.873) | 0.957 | NA | NA | NA | NA | |||
| AFP, ng/mL (≤20 vs. >20) | 4.309 (2.602–7.133) | <0.001 | 5.157 (2.946–9.028) | <0.001 | 2.017 (1.049–3.880) | 0.035 | 2.208 (1.093–4.458) | 0.027 | |||
| Tumor number (single vs. multiple) | 2.496 (1.530–4.072) | <0.001 | 2.137 (1.296–3.524) | 0.003 | 1.748 (0.988–3.093) | 0.055 | 1.479 (0.810–2.703) | 0.203 | |||
| Max size, cm (≤3 vs. >3) | 2.077 (1.302–3.314) | 0.002 | 1.978 (1.230–3.182) | 0.005 | 1.747 (1.037–2.942) | 0.036 | 1.429 (0.824–2.477) | 0.204 | |||
| Cirrhosis | 1.036 (0.474–2.264) | 0.93 | 0.928 (0.423–2.038) | 0.852 | NA | NA | NA | NA | |||
| CTP (A vs. B) | 4.671 (0.635–34.330) | 0.13 | 23.63 (2.845–196.300) | 0.003 | NA | NA | NA | NA | |||
| MELD (≤4.81 vs. 4.81) | 1.309 (0.821–2.088) | 0.258 | 1.006 (0.627– 1.613) | 0.981 | NA | NA | NA | NA | |||
| ALBI | 0.2 | 0.6 | NA | NA | NA | NA | |||||
| 2 | 1.099 (0.691–1.746) | 0.691 | 1.251 (0.782–2.003) | 0.350 | NA | NA | NA | NA | |||
| 3 | 7.103 (0.940–53.666) | 0.0574 | 1.932 (0.261–14.273) | 0.519 | NA | NA | NA | NA | |||
| ALT, U/L (≤40 vs. >40) | 0.923 (0.534–1.594) | 0.773 | 0.637 (0.361–1.124) | 0.120 | NA | NA | NA | NA | |||
| AST, U/L (≤40 vs. >40) | 1.235 (0.677–2.252) | 0.491 | 1.053 (0.576–1.927) | 0.866 | NA | NA | NA | NA | |||
| γ-GT (≤60 vs. >60) | 0.982 (0.606–1.590) | 0.939 | 1.134 (0.692–1.857) | 0.619 | 1.061 (0.594–1.894) | 0.841 | 0.922 (0.467–1.818) | 0.814 | |||
| TBIL, μmol/L (≤17.1 vs. >17.1) | 1.581 (0.992–2.520) | 0.054 | 1.030 (0.635–1.670) | 0.905 | NA | NA | NA | NA | |||
| ALB, g/L (≤43.2 vs. >43.2) | 1.069 (0.613–1.863) | 0.814 | 0.975 (0.627–1.516) | 0.910 | NA | NA | NA | NA | |||
| PLR (≤125.28 vs. >125.28) | 2.379 (1.327–4.267) | 0.004 | 1.873 (1.042–3.370) | 0.036 | 1.285 (0.588–2.809) | 0.530 | 1.078 (0.492–2.363) | 0.851 | |||
| NLR (≤3 vs. >3) | 1.404 (0.876–2.250) | 0.158 | 1.378 (0.852–2.228) | 0.192 | 1.378 (0.794–2.389) | 0.254 | 1.508 (0.870–2.613) | 0.143 | |||
| PNI (≤52.21 vs. >52.21) | 0.736 (0.352–1.536) | 0.414 | 0.874 (0.398–1.923) | 0.739 | 1.111 (0.421–2.930) | 0.832 | 1.595 (0.552–4.612) | 0.389 | |||
| SII (≤324.55 vs. >324.55) | 6.416 (3.438–11.980) | <0.001 | 8.549 (3.911–18.680) | <0.001 | 2.951 (1.350–6.452) | 0.007 | 4.091 (1.545–10.833) | 0.005 | |||
OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; AFP, alpha-fetoprotein; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; ALB, albumin; ALT, alanine aminotransferase; AST, aspartic transaminase; γ-GT, γ-glutamyl transpeptidase; TBIL, total bilirubin; NLR, neutrophil lymphocyte ratio; SII, systemic immune inflammatory index; PLR, platelet lymphocyte ratio; PNI, prognostic nutritional index.